Repligen Corporation
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Olivier Dominique Loeillot
- Full Time Employees
- 2,000
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Building 1 Waltham MA United States 02453
- IPO Date
- Apr 29, 1986
- CIK
- 0000730272
- Website
- repligen.com
- Similar Companies
- Business
- Repligen Corporation is a global life sciences company specializing in the development and commercialization of bioprocessing technologies and systems designed to increase efficiencies in the manufacturing of biological drugs. Its core product portfolio includes upstream and downstream bioprocessing solutions such as tangential flow filtration systems (XCell ATF®, KrosFlo® TFDF®), chromatography systems (KRM® Chromatography System, OPUS® Pre-packed Columns), affinity resins (AVIPure® AAV Affinity Resins), fluid management technologies, process analytical technology (PAT) devices (CTech™ SoloVPE® PLUS System, CTech™ FlowVPE® PLUS System, MAVERICK®, MAVEN®, REBEL®), and cell culture supplements. The company serves a broad range of biologics including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, fusion proteins, mRNA, and cell and gene therapies, targeting biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Founded in 1981 and headquartered in Waltham, Massachusetts, Repligen operates globally with significant market presence in North America, Europe, and Asia-Pacific. Recent major developments include the acquisition of 908 Devices' desktop portfolio of four bioprocessing analytical devices—MAVERICK, MAVEN, REBEL, and ZipChip—for $70 million in cash, which enhances Repligen's process analytical technology offerings across the bioprocess workflow. In 2025, it launched the CTech™ SoloVPE® PLUS System, a UV-based variable pathlength technology device that supports advances in process analytics. Repligen also expanded its strategic footprint through a definitive agreement to acquire ARTeSYN BioSolutions, a manufacturer of innovative process technologies. Additionally, it has formed a partnership with Novasign to integrate AI-powered digital twins technology aimed at streamlining process development and enabling real-time predictive control in bioprocessing operations. The company reported a strong financial performance in 2025 with quarterly revenues exceeding $180 million and upward adjustments in full-year revenue guidance reflecting sustained double-digit growth across all franchises and geographies. Repligen's comprehensive offerings span filtration and fluid management, chromatography, process analytics, and biologic protein products, backed by expert installation and qualification services to optimize bioprocessing equipment. This portfolio diversification and strategic expansion underscore Repligen's position as a technology leader in the bioprocessing industry, supporting the development and manufacturing of biologic drugs globally.
Company News
Repligen Corporation to Present at Jefferies Global Healthcare Conference
Baron SMID Cap ETF Q3 2026 Contributors And Detractors
Repligen Announces $1 Billion Private Convertible Senior Notes Transaction
Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript
What Repligen (RGEN) Said on Its Q3 Earnings Call
Conestoga Small Cap Composite Q3 2026 Portfolio Activity
Repligen (RGEN) Q3 Earnings and Revenues Surpass Estimates
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
Baron Health Care Fund Q3 2026 Top Contributors And Detractors
Repligen Corporation $RGEN Stock Sold by Krilogy Financial LLC
Repligen: A Buy As Its Growth Engine Gears Up
Repligen to Report Third Quarter 2026 Financial Results
Repligen Corp (RGEN) Shares Fall 7.7% -- What GF Score of 85 Tells Investors
Repligen Completes Acquisition of BioLife Solutions
Repligen Corp (RGEN) Stock Up 4.3% but GF Value Says Overvalued -- GF Score: 85/100
BioLife Solutions Shareholders Approve Repligen Merger Agreement
Repligen (NASDAQ:RGEN) Hits New 52-Week High – Still a Buy?
Tidal Investments LLC Raises Holdings in Repligen Corporation $RGEN
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS